Dr. Flavia L. Thomas, D.O.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Michigan State University College of Osteopathic Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 263
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Michigan State University College of Osteopathic Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license K8520 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Texas Faith LLC (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 263
- Services billed
- 6,051
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Detection test by nucleic acid for organism, amplified probe technique | 3,057 | 210 |
| Detection test for candida species (yeast), amplified probe technique | 750 | 123 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 249 | 210 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 150 | 123 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 116 | 98 |
| Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique | 99 | 97 |
| Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | 99 | 97 |
| Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | 99 | 97 |
| Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | 89 | 89 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 43 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $23,858 in research payments for these studies, mostly to the institutions running them.
- OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
Oyster Point Pharma, Inc. · Recruiting · NCT07140783
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.